Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.

“We are pleased to see that a CombinatoRx-derived combination drug candidate has been recognized as a key asset in the proposed acquisition of Fovea, our ophthalmic collaborator,” commented Robert Forrester, Interim President and CEO of CombinatoRx. “This accomplishment reinforces our business strategy of leveraging the CombinatoRx discovery technology platform through strategic collaborations.”




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema